- Home
- PTON vs SUPN Comparison
PTON vs SUPN Comparison
Compare PTON & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTON | SUPN |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PTON | SUPN |
|---|---|---|
| Price | $6.40 | $45.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $9.68 | ★ $63.25 |
| AVG Volume (30 Days) | ★ 10.2M | 782.6K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,455,600,000.00 | $681,539,000.00 |
| Revenue This Year | $1.53 | $8.32 |
| Revenue Next Year | $1.42 | $23.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $4.63 | $29.16 |
| 52 Week High | $10.90 | $57.65 |
Technical Indicators
Market Signals| Indicator | PTON | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 37.93 | 46.31 |
| Support Level | $6.37 | $44.09 |
| Resistance Level | $6.80 | $47.00 |
| Average True Range (ATR) | 0.32 | 1.25 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 9.29 | 57.97 |
Price Performance
Historical ComparisonAbout PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.